Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.33 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.33 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17083811 | 0.92 | L3MBTL1 (0.38) | L3MBTL1 | |
| SCHEMBL17083807 | 0.90 | PRKCA (0.40) | TRPV1ELANEENPP2CNR1PRKCE | |
| SCHEMBL17083808 | 0.88 | TRPV1 (0.38) | TRPV1ELANEENPP2CNR1PRKCE | |
| SCHEMBL17083817 | 0.84 | TRPV1 (0.35) | TRPV1ENPP2CNR1PRKCEPRKCQ | |
| SCHEMBL17083815 | 0.84 | ACHE (0.35) | TRPV1ENPP2CNR1PRKCEPRKCQ | |
| SCHEMBL17083828 | 0.83 | PRKCA (0.39) | TRPV1CNR1PRKCEPRKCQPRKCD | |
| SCHEMBL17083809 | 0.83 | PRKCA (0.39) | TRPV1CNR1PRKCEPRKCQPRKCD | |
| SCHEMBL17083850 | 0.82 | TRPV1 (0.37) | TRPV1ELANEENPP2CNR1PRKCE | |
| SCHEMBL17083819 | 0.81 | ALDH1A1 (0.38) | ENPP2CNR1PRKCEPRKCQPRKCD | |
| SCHEMBL17083822 | 0.81 | TRPV1 (0.44) | TRPV1ELANEPRKCEPRKCQPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328192-B2 | Bio-based monomers and polymers | BEZWADA BIOMEDICAL, LLC (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150259464-A1 | BIO-BASED MONOMERS AND POLYMERS | BEZWADA BIOMEDICAL, LLC | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259464-A1 | BIO-BASED MONOMERS AND POLYMERS | FHIT, MGAM, BPGM | TRPV1 1874/4885ELANE 1177/4885L3MBTL1 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.